Increasing evidence indicates that oxidative damage exists in schizophrenia. Available
literature about possible mechanisms of oxidative stress induction was reviewed …

In the past decade, there has been renewed interest in immune/inflammatory changes and
their associated oxidative/nitrosative consequences as key pathophysiological mechanisms …

Background Management of tardive syndromes (TS) is challenging, with only a few
evidence-based therapeutic algorithms reported in the American Academy of Neurology …

Objective: Recent evidence suggests that adjuvant anti-inflammatory agents could improve
the symptoms of patients with schizophrenia. However, the effects of the adjuvant anti …

Tardive dyskinesia is a serious, disabling and potentially permanent, neurological
hyperkinetic movement disorder that occurs after months or years of taking psychotropic …

Short-term clinical trials of omega-3 polyunsaturated fatty acids (n-3 PUFA) as add-on
therapy in patients with schizophrenia revealed mixed results. The majority of these studies …

Objective: To investigate if ethyl-eicosapentaenoic acid (E-EPA) augmentation improves
antipsychotic efficacy and tolerability in first-episode psychosis (FEP). Method: We …

Background Limited evidence supports a hypothesis suggesting that the symptoms of
schizophrenia may be the result of altered neuronal membrane structure and metabolism …

Background Omega-3 fatty acids, in particular, eicosapentaenoic acid (EPA) have been
suggested as augmentation strategies in the treatment of schizophrenia and related …

Omega-3 treatment studies for multi-episode schizophrenia or clinical high risk for
conversion to psychosis states have had variable, and often negative, results. To examine …